Literature DB >> 15621749

Microenvironmental interactions and survival of CLL B-cells.

Irene Munk Pedersen1, John Reed.   

Abstract

Chronic Lymphocytic Leukemia (CLL) B cells display characteristics consistent with a defect in programmed cell death (apoptosis) and exhibit prolonged survival in vivo. When recovered from peripheral blood or lymphoid tissues from the patient and cultured in vitro, these malignant cells rapidly undergo spontaneous apoptosis. This observation suggests that the selective survival advantage enjoyed by CLL B-cells is not entirely autonomous, raising the possibility of manipulating CLL B-cell survival by iatrogenic means. The extended survival of the neoplastic B-cells creates a permissive soil on which oncogene activation, genetic instability and accumulation of gene mutations favoring disease progression can occur. In addition, such survival-promoting microenvironments can rescue leukemia cells from cytotoxic therapy, giving way to disease relapse. Survival of CLL B-cells is influenced by interactions with non-leukemia cells in the microenvironment of lymph nodes, marrow and other tissues. CLL B-cells have developed many different ways to escape undergoing apoptosis. These include: (a) expression of survival receptor as well as their ligands, giving rise to autocrine survival pathways which are leukemia cell specific; (b) defects in plasma membrane receptor cell signaling, triggered by death receptors such as Fas- and TRAIL; and (c) constitutively active survival signaling pathways such as NFkappaB and PI3K/Akt. Here we discuss some of the molecular mechanisms by which interaction with other cells and factors in the microenvironment provides survival advantages to CLL B-cells in specific in vivo niches, and we suggest some strategies for overcoming these anti-apoptotic mechanisms for improving treatment of CLL.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15621749     DOI: 10.1080/10428190412331272703

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  48 in total

1.  Bone marrow stromal cell-derived vascular endothelial growth factor (VEGF) rather than chronic lymphocytic leukemia (CLL) cell-derived VEGF is essential for the apoptotic resistance of cultured CLL cells.

Authors:  Iris Gehrke; Rajesh Kumar Gandhirajan; Simon Jonas Poll-Wolbeck; Michael Hallek; Karl-Anton Kreuzer
Journal:  Mol Med       Date:  2011-04-14       Impact factor: 6.354

Review 2.  The B-cell receptor signaling pathway as a therapeutic target in CLL.

Authors:  Jennifer A Woyach; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2012-06-19       Impact factor: 22.113

3.  All-trans-retinoic acid promotes trafficking of human concentrative nucleoside transporter-3 (hCNT3) to the plasma membrane by a TGF-beta1-mediated mechanism.

Authors:  Paula Fernández-Calotti; Marçal Pastor-Anglada
Journal:  J Biol Chem       Date:  2010-02-19       Impact factor: 5.157

4.  Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL.

Authors:  Jennifer S Carew; Steffan T Nawrocki; Yelena V Krupnik; Kenneth Dunner; David J McConkey; Michael J Keating; Peng Huang
Journal:  Blood       Date:  2005-09-06       Impact factor: 22.113

5.  Phosphatidylinositol-3-phosphate kinase pathway activation protects leukemic large granular lymphocytes from undergoing homeostatic apoptosis.

Authors:  Andrew E Schade; Jennifer J Powers; Marcin W Wlodarski; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2006-02-16       Impact factor: 22.113

Review 6.  Molecular and cellular mechanisms of CLL: novel therapeutic approaches.

Authors:  Lisa Pleyer; Alexander Egle; Tanja Nicole Hartmann; Richard Greil
Journal:  Nat Rev Clin Oncol       Date:  2009-06-02       Impact factor: 66.675

7.  High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation.

Authors:  Jan A Burger; Maite P Quiroga; Elena Hartmann; Andrea Bürkle; William G Wierda; Michael J Keating; Andreas Rosenwald
Journal:  Blood       Date:  2008-12-12       Impact factor: 22.113

8.  Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach.

Authors:  Matthias Niedermeier; Bryan T Hennessy; Zachary A Knight; Marina Henneberg; Jianhua Hu; Antonina V Kurtova; William G Wierda; Michael J Keating; Kevan M Shokat; Jan A Burger
Journal:  Blood       Date:  2009-03-24       Impact factor: 22.113

9.  Tumorigenic potential and disease manifestations of malignant B-cell variants differing in their fibronectin adhesiveness.

Authors:  Liat Nadav; Vyacheslav Kalchenko; Meir Max Barak; Elizabeth Naparstek; Benjamin Geiger; Ben-Zion Katz
Journal:  Exp Hematol       Date:  2008-08-09       Impact factor: 3.084

Review 10.  Phosphoinositide 3-kinase inhibitors in lymphoma.

Authors:  Emily Curran; Sonali M Smith
Journal:  Curr Opin Oncol       Date:  2014-09       Impact factor: 3.645

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.